Published in Int J Cancer on October 15, 2000
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones (2005) 5.22
Hsp70 interactions with the p53 tumour suppressor protein. EMBO J (2001) 1.62
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood (2009) 1.61
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Lung cancer immunotherapy. Clin Med Res (2005) 1.04
Heat shock proteins: the fountainhead of innate and adaptive immune responses. Cell Stress Chaperones (2000) 1.00
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
Heat-shock proteins as dendritic cell-targeting vaccines--getting warmer. Immunology (2013) 0.98
A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci (2007) 0.97
Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro Oncol (2005) 0.97
Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors. Cell Stress Chaperones (2006) 0.96
Heat shock proteins: stimulators of innate and acquired immunity. Biomed Res Int (2013) 0.92
Integrated Proteomic and Glycoproteomic Analyses of Prostate Cancer Cells Reveal Glycoprotein Alteration in Protein Abundance and Glycosylation. Mol Cell Proteomics (2015) 0.90
Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol (2015) 0.89
Challenges in the development of an autologous heat shock protein based anti-tumor vaccine. Hum Vaccin Immunother (2012) 0.88
Induction of tumor-specific immune response by gene transfer of Hsp70-cell-penetrating peptide fusion protein to tumors in mice. Mol Ther (2009) 0.87
Emerging microfluidic tools for functional cellular immunophenotyping: a new potential paradigm for immune status characterization. Front Oncol (2013) 0.87
Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clin Exp Immunol (2007) 0.86
Natural autoantibodies against heat-shock proteins hsp70 and gp96: implications for immunotherapy using heat-shock proteins. Immunology (2000) 0.86
Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice. World J Gastroenterol (2005) 0.85
Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer (2008) 0.85
Induction of heat shock protein gp96 by immune cytokines. Cell Stress Chaperones (2003) 0.83
Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med (2010) 0.82
Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells. Gene Ther (2003) 0.82
Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Blood (2004) 0.82
Heat shock protein vaccines against glioblastoma: from bench to bedside. J Neurooncol (2015) 0.82
Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci U S A (2004) 0.80
A Mage3/Heat Shock Protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity. Vaccine (2009) 0.80
Heat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treatment of Cancer. Front Immunol (2016) 0.80
Dendritic cells pulsed with hsp70-peptide complexes derived from human hepatocellular carcinoma induce specific anti-tumor immune responses. World J Gastroenterol (2005) 0.79
Identification of peptide mimotopes of gp96 using single-chain antibody library. Cell Stress Chaperones (2010) 0.78
A tale of two pities: autologous melanoma vaccines on the brink. Hum Vaccin Immunother (2012) 0.78
Tumor immunotherapy based on tumor-derived heat shock proteins (Review). Oncol Lett (2013) 0.78
Autologous heat-shock protein vaccines. Hum Vaccin Immunother (2013) 0.77
Oncolytic virotherapy for urological cancers. Nat Rev Urol (2016) 0.76
Targeting hepatitis B virus antigens to dendritic cells by heat shock protein to improve DNA vaccine potency. World J Gastroenterol (2007) 0.75
Phenotypically distinct helper NK cells are required for gp96-mediated anti-tumor immunity. Sci Rep (2016) 0.75
Gastric cancer-derived heat shock protein-gp96 peptide complex enhances dendritic cell activation. World J Gastroenterol (2017) 0.75
Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg (2000) 13.24
Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol (2000) 4.48
CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity (2001) 4.16
CD91: a receptor for heat shock protein gp96. Nat Immunol (2000) 3.78
A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science (1995) 3.58
Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet (1993) 3.42
Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med (1993) 2.96
Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A (1986) 2.94
Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (1997) 2.92
The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer (1999) 2.90
Community health worker performance in the management of multiple childhood illnesses: Siaya District, Kenya, 1997-2001. Am J Public Health (2001) 2.64
Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med (1997) 2.59
Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet (1999) 2.29
Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. EMBO J (1993) 2.25
Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci U S A (1994) 2.23
Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut (2005) 2.17
Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med (1996) 2.16
Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology (1998) 2.15
Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 2.15
Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol (2001) 2.06
Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer (1999) 2.03
Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest (1998) 2.02
Surgical management of intra-abdominal desmoid tumours. Br J Surg (2000) 2.01
Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol (1994) 1.98
Heteroclitic immunization induces tumor immunity. J Exp Med (1998) 1.92
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut (2006) 1.87
Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology (1998) 1.86
Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer (2001) 1.86
Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol (2000) 1.83
Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. Cancer (2000) 1.78
Small bowel involvement in Crohn's disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. Gut (2005) 1.78
Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol (1997) 1.77
Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol (1997) 1.75
Acute renal failure in falciparum malaria--increasing prevalence in some areas of India--a need for awareness. Nephrol Dial Transplant (1996) 1.71
Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med (1999) 1.71
Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96. Int J Cancer (1996) 1.54
Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. Endoscopy (2006) 1.49
Keratin 8 Y54H and G62C mutations are not associated with inflammatory bowel disease. Dig Liver Dis (2004) 1.45
Extraskeletal osteosarcoma: analysis of outcome of a rare neoplasm. Sarcoma (2000) 1.42
Safety and efficacy of repeated shockwave lithotripsy of gallstones with and without adjuvant bile acid therapy. Gastroenterology (1997) 1.41
Development and quality evaluation of honey based carrot candy. J Food Sci Technol (2011) 1.41
Neuropsychiatric presentations in a case of infective endocarditis. J Assoc Physicians India (1994) 1.39
[Food-dependent Cushing syndrome of long standing with mild clinical features]. Dtsch Med Wochenschr (2000) 1.38
Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas. Cancer Res (1987) 1.38
ESPEN Guidelines on Enteral Nutrition: Geriatrics. Clin Nutr (2006) 1.37
Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem (2001) 1.37
Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg (2001) 1.36
Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol (1999) 1.36
Heat shock protein vaccines against cancer. J Immunother Emphasis Tumor Immunol (1993) 1.35
Diagnostic yield of wireless capsule enteroscopy in comparison with computed tomography enteroclysis. Endoscopy (2003) 1.34
Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J Immunol (2000) 1.34
Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther (2006) 1.33
Is there a role for incomplete resection in the management of retroperitoneal liposarcomas? J Am Coll Surg (2001) 1.32
Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol (1989) 1.30
Soft tissue tumors of the abdominal wall: analysis of disease patterns and treatment. Arch Surg (2001) 1.29
Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase. Biochemistry (1988) 1.28
The dual nature of specific immunological activity of tumor-derived gp96 preparations. J Exp Med (1999) 1.27
The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein. Proc Natl Acad Sci U S A (2001) 1.27
Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: a clinicopathologic study of 25 patients and 26 tumors. Cancer (1998) 1.27
Human homologue of murine tumor rejection antigen gp96: 5'-regulatory and coding regions and relationship to stress-induced proteins. Proc Natl Acad Sci U S A (1990) 1.26
Higher expression of glucocorticoid receptor in peripheral mononuclear cells in inflammatory bowel disease. Am J Gastroenterol (2000) 1.26
Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today (1988) 1.24
Confirmed angiosarcoma: prognostic factors and outcome in 50 prospectively followed patients. Sarcoma (2000) 1.24
Does passage of a patency capsule indicate small-bowel patency? A prospective clinical trial? Endoscopy (2005) 1.22
Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer (1999) 1.21
Epithelioid sarcoma: clinical behavior and prognostic factors of survival. Ann Surg Oncol (1997) 1.20
Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer (2000) 1.20
Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys (2000) 1.20
A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut (2003) 1.19
Saturation, competition, and specificity in interaction of heat shock proteins (hsp) gp96, hsp90, and hsp70 with CD11b+ cells. J Immunol (2000) 1.19
Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut (2002) 1.17
Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography. J Immunol Methods (1997) 1.16
Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery (2000) 1.15
The serologically unique cell surface antigen of Zajdela ascitic hepatoma is also its tumor-associated transplantation antigen. Int J Cancer (1984) 1.14
A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. J Immunol (1999) 1.12
Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med (1997) 1.12
Case report. Orbital metastasis from gall bladder carcinoma. Br J Radiol (2002) 1.11
Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol (2001) 1.11
5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors. Proc Natl Acad Sci U S A (1987) 1.10
Prevalence of malnutrition in 1760 patients at hospital admission: a controlled population study of body composition. Clin Nutr (2003) 1.10
Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer (1998) 1.09
Thalidomide for treatment of severe intestinal bleeding. Gut (2004) 1.09
Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Ann Oncol (2002) 1.09
Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther (2004) 1.09
The Forkhead factor FoxQ1 influences epithelial differentiation. J Cell Physiol (2011) 1.08
Relationship between the use of unconventional therapies and disease-related concerns: a study of patients with inflammatory bowel disease. J Psychosom Res (1996) 1.08
Nutrition in the elderly. Best Pract Res Clin Gastroenterol (2001) 1.07
Molecular heterogeneity of tumor rejection antigen/heat shock protein GP96. Int J Cancer (1995) 1.07
Anemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci (1994) 1.06
Adult soft tissue sarcoma. Aust N Z J Surg (1999) 1.06
Assessment of autonomic dysfunction in Guillain-Barré syndrome and its prognostic implications. Acta Neurol Scand (1987) 1.05
Fetal translocation and metabolism of PAH obtained from coal fly ash given intratracheally to pregnant rats. J Toxicol Environ Health (1986) 1.05
The endoplasmic reticular heat shock protein gp96 is transcriptionally upregulated in interferon-treated cells. J Exp Med (1994) 1.05
Spectrum of renal cortical necrosis in acute renal failure in eastern India. Postgrad Med J (1995) 1.04
Is tube feeding with elemental diets a primary therapy of Crohn's disease? Klin Wochenschr (1984) 1.04
Multifocal extremity sarcoma: an uncommon and controversial entity. Ann Surg Oncol (1998) 1.04
Desmoid tumors of the head and neck--a clinical study of a rare entity. Head Neck (2000) 1.04
Nutritional assessment and management in hospitalised patients: implication for DRG-based reimbursement and health care quality. Clin Nutr (2005) 1.03